Albireo to participate in cowen and h.c. wainwright global investor conferences

Boston, feb. 23, 2021 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming cowen 41st annual health care conference march 1-4, 2021. ron cooper, president and chief executive officer of albireo, will take part in the new drug launches panel on wednesday, march 3, 2021 at 10:20am et. members of the management team will also host meetings with investors on march 2.
ALBO Ratings Summary
ALBO Quant Ranking